Comparison of the Effect of Clopidogrel and Ticagrelor on the Development of No-Reflow Phenomenon After Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction
Cardiovascular Reviews · 2023
DOI: 10.26689/cr.v1i1.4965 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Reviews, 2023. Verfasst von Emrah Yesil und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
No-reflow phenomenon (NRP) is one of the most important factors affecting myocardial reperfusion.
Objective
In this study, we investigated the effect of ticagrelor and clopidogrel on the development of NRP in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI).
Methods
Our single-center, retrospective study included 200 patients with AMI who underwent PCI. The patients were divided into two groups according to the antiplatelet regimen given before PCI: clopidogrel- and ticagrelor-loaded groups. NRP was defined based on TIMI flow classification or post-procedural ST segment resolution. The difference in the parameters between patients with no-reflow and patients with normal flow as well as the effect of ticagrelor and clopidogrel on NRP were evaluated.
Results
There was no difference in baseline characteristics between patients with no-reflow and patients with normal flow. The number of patients with ST-elevation myocardial infarction was higher in the ticagrelor-loaded group compared with the clopidogrel-loaded group (P = 0.013). Age, aspartate aminotransferase (AST), C-reactive protein (CRP), peak creatine kinase MB (CK-MB), diabetes mellitus (DM) rate, length of stent, number of stents, and number of patients with low ejection fraction were significantly higher in the no-reflow group compared with the normal flow group. The rate of NRP development was significantly lower in ticagrelor-loaded patients (19% P = 0.001), independent of other independent variables, including age, DM, AST, CRP level, number of stents implanted, and type of myocardial infarction (odds ratio = 0.228, 95% confidence interval = 0.102–0.512, P < 0.001).
Conclusion
Ticagrelor is superior to clopidogrel in preventing the development of NRP.
Zitieren
APA
Yesil, E., Uyar, H., Örsçelik, Ö., Özkan, B., Çelik, A., Özcan, İ. T., & Akkuş, M. N. (2023). Comparison of the Effect of Clopidogrel and Ticagrelor on the Development of No-Reflow Phenomenon After Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction. Cardiovascular Reviews. https://doi.org/10.26689/cr.v1i1.4965
Vancouver
Yesil E, Uyar H, Örsçelik Ö, Özkan B, Çelik A, Özcan İT, et al. Comparison of the Effect of Clopidogrel and Ticagrelor on the Development of No-Reflow Phenomenon After Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction. Cardiovascular Reviews. 2023. doi:10.26689/cr.v1i1.4965
BibTeX
@article{Yesil2023,
author = {Yesil, Emrah and Uyar, Hakan and Örsçelik, Özcan and Özkan, Buğra and Çelik, Ahmet and Özcan, İsmail Türkay and Akkuş, Mehmet Necdet},
title = {Comparison of the Effect of Clopidogrel and Ticagrelor on the Development of No-Reflow Phenomenon After Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction},
journal = {Cardiovascular Reviews},
year = {2023},
doi = {10.26689/cr.v1i1.4965}
}
EUVIMED